Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…Abstract Number: 1560 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab
Background/Purpose : There is a lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA). Therefore, a modified version of the minimal disease activity (mMDA)1…Abstract Number: 1561 • 2017 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition characterized by peripheral arthritis and psoriatic skin lesions requiring therapies that control both skin and joint symptoms.…Abstract Number: 1562 • 2017 ACR/ARHP Annual Meeting
Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Background/Purpose: We are currently witnessing a diversification of the available biotherapies (bDMARDs) for psoriatic arthritis (PsA), with the arrival of new classes of medication. Those…Abstract Number: 1563 • 2017 ACR/ARHP Annual Meeting
Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing Spondylitis (AS) is not only characterized by pathological bone formation leading to ankylosis, but also by bone loss which may lead to vertebral…Abstract Number: 1564 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns, Survival and Long-Term Effectiveness of Biological Agents in Psoriatic Arthritis Patients
Background/Purpose: The incorporation of biological disease modifying drugs (b-DMARD) has substantially improved the outcome of patients with Psoriatic Arthritis (PsA). Our aim was to evaluate…Abstract Number: 1565 • 2017 ACR/ARHP Annual Meeting
Depression and Fatigue in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to bony ankyloses. The disease occurs in early adulthood, a critical stage in life,…Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…
ACR Meeting Abstracts